Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 60719-84-8 Chemical Structure| 60719-84-8

Structure of Amrinone
CAS No.: 60719-84-8

Chemical Structure| 60719-84-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Amrinone is a type 3 pyridine phosphodiesterase inhibitor used in the treatment of congestive heart failure.

Synonyms: Inamrinone; WIN 40,680

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Amrinone

CAS No. :60719-84-8
Formula : C10H9N3O
M.W : 187.20
SMILES Code : NC1=CC(=CNC1=O)C1=CC=NC=C1
Synonyms :
Inamrinone; WIN 40,680
MDL No. :MFCD00083228
InChI Key :RNLQIBCLLYYYFJ-UHFFFAOYSA-N
Pubchem ID :3698

Safety of Amrinone

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P301+P310
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02174029 - Completed - Canada, British Columbia ... More >> Royal Columbian Hospital New Westminster, British Columbia, Canada, V3L 3W7 Less <<
NCT00060840 - Completed - -
NCT00060840 Congestive Heart Failure Phase 2 Completed - United States, New Jersey ... More >> Newark Beth Isreal Medical Center Newark, New Jersey, United States, 07112 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio University of Cincinnati Cincinnati, Ohio, United States, 45219 Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 United States, Pennsylvania Allegheny General Hospital Pittsburgh, Pennsylvania, United States, 15212 United States, Texas Baylor University Medical Center Dallas, Texas, United States, 75226 University of Texas/St. Paul Medical Center Dallas, Texas, United States, 75390 Texas Heart Institute Houston, Texas, United States, 20345 Germany Herz-und Diabeteszentrum Nordrhein-Westfalen Gergstrab, Bad Oeynhausen, Germany, 32545 Deutsches Herfzzentrum Berlin Augustenburger Platz, Berlin, Germany, 13353 United Kingdom Harefield Hospital Harefield, Middlesex, United Kingdom, UB96JH Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.34mL

1.07mL

0.53mL

26.71mL

5.34mL

2.67mL

53.42mL

10.68mL

5.34mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

[1]Asif M. Phosphodiesterase-III Inhibitors Amrinone and Milrinone on Epilepsy and Cardiovascular Activities. N Am J Med Sci. 2012 Oct;4(10):499-502.

[2]Xiong W, Ferrier GR, Howlett SE. Diminished inotropic response to amrinone in ventricular myocytes from myopathic hamsters is linked to depression of high-gain Ca2+-induced Ca2+ release. J Pharmacol Exp Ther. 2004 Aug;310(2):761-73.

[3]Ichioka S, Nakatsuka T, Ohura N, Sato Y, Harii K. Clinical use of amrinone (a selective phosphodiesterase III inhibitor) in reconstructive surgery. Plast Reconstr Surg. 2001 Dec;108(7):1931-7

[4]Hachisu M, Nomura M, Fujishima K. [Effects of amrinone, an inhibitor of c-AMP-specific phosphodiesterases, on neointimal hyperplasia after balloon injury in rats]. Nihon Yakurigaku Zasshi. 1998 Oct;112(4):267-74. Japanese

[5]Pagel PS, Hettrick DA, Warltier DC. Amrinone enhances myocardial contractility and improves left ventricular diastolic function in conscious and anesthetized chronically instrumented dogs. Anesthesiology. 1993 Oct;79(4):753-65

[6]Ochiai Y, Morita S, Tanoue Y, Kawachi Y, Tominaga R, Yasui H. Effects of amrinone, a phosphodiesterase inhibitor, on right ventricular/arterial coupling immediately after cardiac operations. J Thorac Cardiovasc Surg. 1998 Jul;116(1):139-47

[7]Perez-Baliño NA, Masoli OH, Meretta AH, Rodriguez A, Cragnolino DE, Perrone S, Boullon F, Mele E, Palacios I, Brown KA. Amrinone stimulation test: ability to predict improvement in left ventricular ejection fraction after coronary bypass surgery in patients with poor baseline left ventricular function. J Am Coll Cardiol. 1996 Nov 15;28(6):1488-92

 

Historical Records

Categories